IN THE CLAIMS:

Listing of Claims:

1-30 (Cancelled).

31. (Currently amended) A method ~~of~~ for treatment of ~~the human or animal body~~ a metabolic disorder or condition related to an α-galactosidase A deficiency, said method comprising administering to a subject in need thereof an effective, non-toxic amount of a pharmaceutical composition comprising:

(a) an expression cassette operably linked to:

(i) a myosin light chain enhancer;

(ii) a promoter selected from a myosin heavy chain promoter and a viral promoter; and

(iii) a polynucleotide sequence encoding a polypeptide of therapeutic use; or

(b) a vector comprising said expression cassette; or

(c) a viral strain comprising said expression cassette

combined with a pharmaceutically acceptable carrier or diluent.

32. (Previously presented) The method of claim 31, wherein said vector is a plasmid vector or a viral vector.

33. (Previously presented) The method of claim 31, wherein said expression cassette is administered as a naked nucleic acid construct.

34. (Previously presented) The method of claim 31, wherein said pharmaceutical composition is formulated for intramuscular administration.

35. (Previously presented) The method of claim 31, wherein said myosin light chain enhancer is a myosin light chain 1/3 enhancer.

36-39 (Cancelled).

40. (Previously presented) The method of claim 31, wherein said viral promoter is a cytomegalovirus promoter or a herpes simplex virus promoter.

41. (Currently amended) The method of claim 31, wherein said vector ~~further~~ comprises fish or mammalian genomic sequences flanking said expression cassette.

42. (Currently amended) The method of claim 31, wherein said vector ~~further~~ comprises viral genomic sequences flanking said expression cassette.

43-50 (Cancelled).

51. (Currently amended) The method of claim 31, wherein said polynucleotide sequence comprises a heterologous gene.

52-57 (Cancelled).

58. (Currently amended) A method ~~of~~ for treatment of ~~the human or animal body~~ a metabolic disorder or condition related to an α-galactosidase A deficiency, said method comprising administering to a subject in need thereof an effective, non-toxic amount of a pharmaceutical composition comprising:

(a) an expression cassette operably linked to:

(i) a myosin light chain enhancer;

(ii) a promoter selected from a myosin heavy chain promoter and a viral promoter; and

(iii) a polynucleotide sequence encoding a polypeptide of therapeutic use which is not a blood coagulation factor; or

(b) a vector comprising said expression cassette; or

(c) a viral strain comprising said expression cassette

combined with a pharmaceutically acceptable carrier or diluent.

59. (Previously presented) The method of claim 58, wherein said vector is a plasmid vector or a viral vector.

60. (Previously presented) The method of claim 58, wherein said expression cassette is administered as a naked nucleic acid construct.

61. (Previously presented) The method of claim 58, wherein said pharmaceutical composition is formulated for intramuscular administration.

62. (Previously presented) The method of claim 58, wherein said myosin light chain enhancer is a myosin light chain 1/3 enhancer.

63-66 (Cancelled).

67. (Previously presented) The method of claim 58, wherein said viral promoter is a cytomegalovirus promoter or a herpes simplex virus promoter.

68. (Currently amended) The method of claim 58, wherein said vector ~~further~~ comprises fish or mammalian genomic sequences flanking said expression cassette.

69. (Currently amended) The method of claim 58, wherein said vector ~~further~~ comprises viral genomic sequences flanking said expression cassette.

70-77 (Cancelled)

78. (Currently amended) The method of claim 58, wherein said polynucleotide sequence comprises a heterologous gene.

79-96 (Cancelled).

97. (New) The method of claim 31 or 58, wherein the subject in need of treatment is an animal.

98. (New) The method of claim 97, wherein the animal is a human.